Q-omics provides the consensus-scored ABTB2 profile across patient tissues and cancer cell-line models. ABTB2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ABTB2 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ABTB2 RNA expression shows 18,682 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where ABTB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABTB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABTB2 survival associations across molecular data types. ABTB2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABTB2 RNA expression–survival associations across cancer types. High ABTB2 expression shows unfavorable associations in BLCA, CESC, LUSC and PAAD, but favorable associations in SKCM and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for ABTB2 RNA expression.
This table summarizes ABTB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ABTB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABTB2 shows lower tumor expression in KIRC and KIRP and higher tumor expression in THCA, LUAD, UCEC and LUSC. The THCA box plot shows higher ABTB2 RNA expression in tumor versus normal tissue (log2 FC = +2.338, t-test p < 0.001).
This table shows molecular features associated with ABTB2 in patient tissues and cancer cell lines. In patient samples, ABTB2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ABTB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
